IXICO plc

("IXICO" or the "Company")

Non-Executive Director Appointment

IXICO plc (AIM: IXI) ('IXICO' or the 'Company'), the data analytics company delivering insights in neuroscience, is pleased to announce the appointment of Kate Rogers as a Non-Executive Director and Chair of the Audit Committee with effect from 21 January 2022.

John Bradshaw, who has served as a non-executive director and Chair of the Audit Committee since October 2013, has informed the Board of his intention to retire owing to his length of service on the IXICO Board with effect from 30 April 2022. His responsibilities as IXICO's Chair of the Audit Committee will be assumed by Kate Rogers with immediate effect.

Kate is currently leading the transformation of Glaxo SmithKline's global finance organisation having previously worked as CFO for Laboratoire Glaxo SmithKline SaS (GSK France) as well as other senior finance roles within GSK. Kate holds a Bachelor of Science degree in Engineering from Oxford University and qualified as a Chartered Management Accountant in 1999.

Charles Spicer, Chair of the Board said: "Personally, and on behalf of the Board, I would like to thank John for the outstanding contribution he has made to IXICO over the last nine years. His support for the Company and wise advice to us all has been invaluable. We wish him well. Separately, we are delighted to welcome Kate to IXICO and look forward to benefitting from her broad and deep experience of both the pharmaceutical sector and international finance."

Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Katherine Jane Rogers (previously Wall) (age 55) has held the following directorships or partnerships in the past five years:

Ms Rogers does not currently hold any shares in the Company.

There is no further information required to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 (g) of the AIM Rules for Companies.

For further information please contact:

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com